AUS
NZ
UK
CA
USA
IND
IXICO plc (AIM:IXI), a leading precision analytics company specializing in neuroscience, is pleased to announce the appointment of Bram Goorden as Chief Executive Officer (CEO), effective from 19 August 2024. Bram will succeed Giulio Cerroni, who is set to retire by the end of 2024. Giulio will step down as a director on 16 August 2024 and will support the transition to ensure a smooth handover.
Extensive Leadership Experience
Bram Goorden brings over two decades of leadership experience in the BioPharma and precision medicine sectors. His extensive background includes key roles where he has successfully shaped commercial strategies, driven revenue growth, and delivered significant shareholder value. With a strong foundation in central nervous system (CNS) medicine, Bram's established networks and sector-specific expertise make him an excellent fit for IXICO's strategic goals.
Career Highlights
Bram's most recent roles include C-level positions at Eagle Genomics Limited, where he forged vital industry alliances for their AI platform, and at NASDAQ-listed SOPHiA Genetics Inc, where he expanded the company’s presence in the US and secured key partnerships with pharmaceutical companies. His previous experience as VP International Business at Foundation Medicine Inc. saw him enhance the company's global footprint in precision medicine, collaborating with major BioPharma partners. Additionally, as the division CEO of US-based Prometheus Laboratories, Bram integrated the company into Nestle Health Science SA, significantly enhancing shareholder value.
Neuroscience Expertise
Bram's expertise in neuroscience is further demonstrated through his board-level roles at Mantis Photonics AB, a company that utilizes retinal image biomarker analysis for non-invasive detection of neurodegenerative diseases, and Cerecin Inc, a clinical development company focused on treatments for neurodegenerative diseases. He began his career as a management consultant at Accenture, which laid the foundation for his impressive career trajectory.
Strategic Vision for IXICO
With his strong background in BioPharma and precision medicine, Bram is well-positioned to lead IXICO in its mission to deliver intelligent insights in neuroscience. His appointment is expected to drive the company’s growth and reinforce its position as a leader in the field. The Board of IXICO is confident that Bram's leadership will bring significant value to the company and its shareholders.
